Salipro Biotech Secures Key U.S. Patent for Membrane Protein Platform, Extending Protection Until 2042
Key Insights
Salipro Biotech (search) received U.S. Patent No. 12,383,501 for "Production of Salipro Particles," extending IP protection for its membrane protein stabilization platform until June 2042.
The patent protects methods for direct extraction and purification of functional membrane proteins (search), enabling access to challenging targets like GPCRs (search), ion channels (search), and SLC transporters (search).
The company's global patent portfolio now encompasses over 60 granted patents across major pharmaceutical markets including the U.S., EU, China, and Japan.
Salipro Biotech (search) AB announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,383,501, entitled "Production of Salipro Particles," extending the company's intellectual property protection for its Salipro® platform technologies until June 2042. The Stockholm-based biotech company specializes in enabling drug discovery against challenging membrane protein targets.
Strengthening Global IP Position
The newly granted U.S. patent strengthens Salipro Biotech (search)'s position as a global leader in membrane protein stabilization and expands its intellectual property estate across major pharmaceutical markets. The patent protects a key method enabling the direct extraction and purification of functional membrane proteins (search), an essential capability for accessing previously inaccessible targets such as GPCRs (search), ion channels (search) and SLC transporters (search).
"This new U.S. patent represents an important milestone in the continued expansion of our global IP portfolio," said Jens Frauenfeld, CEO of Salipro Biotech (search). "Our Salipro® platform is already powering partnered drug discovery programs worldwide, and this patent further enhances the defensibility and value of our platform for our strategic partners."
Comprehensive Patent Portfolio
Salipro Biotech (search)'s global patent estate now includes over 60 granted patents spanning the U.S., EU, China, Japan, Australia, Singapore, and other major life-science markets. Together, these patents protect the core elements of the Salipro® technology, which stabilizes membrane proteins (search) in their native lipid environment to deliver high-quality functional targets for small-molecule drug discovery, biologics development as well as structure-based drug design.
Platform Technology Applications
The Salipro® platform technology enables researchers to work with membrane proteins (search) that have traditionally been difficult to study and target for drug development. By maintaining these proteins in their native lipid environment, the platform provides functional targets suitable for various drug discovery approaches, including small-molecule development, biologics creation, and structure-based drug design methodologies.
The privately held biotech company has established multiple research collaborations with leading pharmaceutical and biotech companies worldwide, leveraging its fully owned intellectual property portfolio underlying the Salipro® platform technology.